祛湿化瘀方对脂肪肝大鼠脂联素游离脂肪酸代谢路径的影响_医学论文.docVIP

祛湿化瘀方对脂肪肝大鼠脂联素游离脂肪酸代谢路径的影响_医学论文 祛湿化瘀方对脂肪肝大鼠脂联素游离脂肪酸代谢路径的影响_医学论文 作者：李红山, 冯琴, 许丽莉 陈少东 李雪梅, 胡义扬 【摘要】 目的：探讨祛湿化瘀方防治脂肪肝的作用及其对脂联素（adiponectin, ADP）游离脂肪酸（free fatty acid, FFA）代谢路径的影响。方法：采用Wistar雄性大鼠，以四氯化碳（carbon tetrachloride, CCl4）皮下注射复合高脂低蛋白饮食制备大鼠脂肪肝模型。在造模开始2周后，将40只造模大鼠随机分为模型组和高、中、低剂量祛湿化瘀方组，灌胃用药2周。检测肝组织甘油三酯（triglyceride, TG）、FFA含量；观察肝组织病理变化（苏木精和伊红染色、油红O染色）；酶联免疫吸附测定检测血清ADP和肝组织脂联素受体2（adiponectin receptor 2, AdipoR2）、丙二酰辅酶A（malonyl）、腺苷酸活化的蛋白激酶（AMP）、脂肪酸合成酶（fatty acid synthase, FAS）、乙酰辅酶A羧化酶（acetyl）、肉毒碱脂酰转移酶1（carnitine palmitoyltransferase）含量的变化。 结果：与正常组比较，模型组大鼠肝组织出现明显大泡样脂肪变性；肝组织TG、FFA、FAS、ACCase和malonyl含量显著升高，血清ADP及肝组织AdipoR2、AMPK和CPT含量明显降低。高、中、低剂量祛湿化瘀方均可使脂肪肝大鼠肝脏的病理改变显著减轻，肝组织TG、FFA含量降低；高剂量祛湿化瘀方可使模型大鼠肝组织FAS、ACCase和malony1含量显著降低；高、中剂量祛湿化瘀方均能明显升高血清ADP和肝组织AdipoR2、AMPK、CPT含量。结论：祛湿化瘀方可通过提高血清脂联素水平，改善低脂联素血症，影响ADP代谢路径治疗大鼠脂肪肝。 【关键词】 脂肪肝 游离脂肪酸 脂联素 腺苷酸活化蛋白激酶 祛湿化瘀方 大鼠 Methods: Forty Wistar male rats were used to establish the NAFLD model by subcutaneous injection of carbon tetrachloride (CCl4) for 4 weeks (twice weekly) along with highse QSHYD group and lowdose QSHYD group. Another six rats were used as normal control. After 2week treatment, the following indexes were detected: (1) liver pathology (2) contents of serum adiponectin (ADP) and liver triglyceride (TG) (3) concentrations of liver FFA, adiponectin receptor 2 (AdipoR2), malonylcoenzyme A (malony1CoA), AMPactivated protein kinase (AMPK), acetylCoA carboxylase (ACCase), fatty acid synthase (FAS) and carnitine palmitoyl transferase1 (CPT1). Results: Compared with the normal group, there were physiological changes associated with hepatic steatosis and inflammation in liver tissues in the untreated group as observed by oil red O staining and HE staining. The TG, FFA, malony1CoA, FAS, and ACCase concentrations in liver tissues in the untreated group were elevated significantly. While the contents of ADP in serum and AdipoR2, CPT1 and AMPK in liver tissues in the untreated group were decreased markedly. The pathological d